Heron Therapeutics - HRTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 89.39%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.64
▼ -0.07 (-2.58%)

This chart shows the closing price for HRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Heron Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRTX

Analyst Price Target is $5.00
▲ +89.39% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Heron Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 89.39% upside from the last price of $2.64.

This chart shows the closing price for HRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Heron Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
3/13/2024Needham & Company LLCBoost TargetBuy$4.00 ➝ $5.00Low
11/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$5.00 ➝ $4.00Low
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00Low
7/25/2023Needham & Company LLCLower TargetBuy$6.00 ➝ $5.00Low
7/10/2023Cantor FitzgeraldReiterated RatingOverweightLow
4/21/2023Needham & Company LLCReiterated RatingBuy$7.00Low
3/24/2023Evercore ISILower TargetOutperform$15.00 ➝ $10.00Low
3/24/2023Needham & Company LLCLower TargetBuy$8.00 ➝ $7.00Low
11/15/2022Evercore ISILower Target$15.00Low
11/9/2022Needham & Company LLCLower TargetBuy$10.00 ➝ $8.00Low
8/15/2022CowenLower Target$5.50N/A
6/30/2022Needham & Company LLCLower TargetBuy$14.00 ➝ $10.00Low
5/10/2022CowenLower Target$13.00 ➝ $7.50High
5/10/2022Cantor FitzgeraldLower Target$20.00 ➝ $12.00High
5/10/2022CowenLower Target$13.00 ➝ $7.50High
3/1/2022CowenLower Target$31.00 ➝ $13.00High
3/1/2022Needham & Company LLCLower Target$24.00 ➝ $16.00High
3/1/2022Cantor FitzgeraldLower TargetOverweight$26.00 ➝ $20.00High
7/23/2021Jefferies Financial GroupReiterated RatingBuy$25.00Medium
5/13/2021Stifel NicolausReiterated RatingBuy$27.00High
12/2/2020SVB LeerinkBoost TargetOutperform$21.00 ➝ $24.00Medium
9/8/2020Stifel NicolausReiterated RatingBuyMedium
8/6/2020Northland SecuritiesInitiated CoverageBuy$35.00Medium
8/6/2020Stifel NicolausReiterated RatingBuy$21.00Medium
6/30/2020SVB LeerinkLower TargetOutperform$26.00 ➝ $19.00Low
6/29/2020Stifel NicolausInitiated CoverageBuy$21.00Medium
6/22/2020Northland SecuritiesInitiated CoverageBuy$47.00High
5/26/2020GuggenheimInitiated CoverageBuy$24.00Medium
5/18/2020FIXInitiated CoverageAddLow
5/6/2020Stifel NicolausReiterated RatingBuy$29.00Medium
4/15/2020Needham & Company LLCReiterated RatingBuy$44.00High
3/2/2020Stifel NicolausReiterated RatingBuy$29.00Low
3/2/2020Needham & Company LLCLower TargetBuy$48.00 ➝ $44.00High
2/20/2020Cantor FitzgeraldReiterated RatingBuy$41.00N/A
2/20/2020Needham & Company LLCLower TargetBuy$50.00 ➝ $48.00High
1/15/2020CowenReiterated RatingBuy$40.00Low
11/13/2019Northland SecuritiesReiterated RatingBuy$47.00High
11/12/2019SVB LeerinkReiterated RatingOutperformMedium
10/3/2019JMP SecuritiesLower TargetOutperform ➝ Market Outperform$38.00 ➝ $32.00High
10/1/2019JMP SecuritiesReiterated RatingOutperform$33.00 ➝ $38.00High
10/1/2019CowenReiterated RatingBuy$40.00High
8/13/2019Evercore ISIReiterated RatingBuy$75.00Low
8/5/2019Stifel NicolausReiterated RatingBuy$38.00Low
8/5/2019Northland SecuritiesReiterated RatingBuy$55.00Low
5/9/2019CowenReiterated RatingBuyMedium
5/9/2019Northland SecuritiesReiterated RatingBuy$55.00High
5/1/2019Stifel NicolausReiterated RatingBuy$38.00High
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/21/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/20/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/21/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Heron Therapeutics logo
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.64
Low: $2.51
High: $2.74

50 Day Range

MA: $2.75
Low: $2.36
High: $3.06

52 Week Range

Now: $2.64
Low: $0.50
High: $3.22

Volume

2,308,607 shs

Average Volume

1,358,640 shs

Market Capitalization

$396.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Heron Therapeutics?

The following Wall Street research analysts have issued research reports on Heron Therapeutics in the last twelve months: Cantor Fitzgerald, Needham & Company LLC, and StockNews.com.
View the latest analyst ratings for HRTX.

What is the current price target for Heron Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Heron Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 89.4%. Needham & Company LLC has the highest price target set, predicting HRTX will reach $5.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $5.00 for Heron Therapeutics in the next year.
View the latest price targets for HRTX.

What is the current consensus analyst rating for Heron Therapeutics?

Heron Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HRTX will outperform the market and that investors should add to their positions of Heron Therapeutics.
View the latest ratings for HRTX.

What other companies compete with Heron Therapeutics?

How do I contact Heron Therapeutics' investor relations team?

Heron Therapeutics' physical mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 251-4400 and its investor relations email address is [email protected]. The official website for Heron Therapeutics is www.herontx.com. Learn More about contacing Heron Therapeutics investor relations.